| Ticker Symbol: | POZN |
|---|---|
| Exchange: | NASD |
| Contact Info: | 1414 Raleigh Road Chapel Hill NC 27517 919 913-1030 |
| CEO/President: | John R. Plachetka Ph.D. |
| Industry: | Medical - Drugs / Standard Industry Code: 2834 |
| Description: | Pozen Inc. is pharmaceutical development company committed to building a portfolio of products with significant commercial potential in select therapeutic areas. Its initial area of focus is migraine, where the company have built a portfolio of four product candidates through a combination of innovation and in-licensing. Its lead product candidate is MT 100, which the company is developing as an oral first-line therapy for the treatment of migraine. |
| Shares Outstanding: | 29,760 (000) | Market Value: | 244,360 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 58.70% | Number of Inst.Shareholders: | 17.00% |
| Last Quarter Sales: | 33.12 ($Mil.) | Last Quarter Net Income: | 13.33 ($Mil.) |
| Last Quarter EPS: | 0.43 | P/E Ratio: | 16 |
| Most Recent Earnings: | -0.25 on 05/08/08 | Earnings Per Share: | 0.52 |
| Most Recent Split: | Annual Dividend Rate: | 0 | |
| Most Recent Dividend: | Annual Dividend Yield: | 0% |

| PFIZER INC | -40.50 | 15.14 | |
| JOHNSON AND JOH | -19.70 | 55.85 | |
| MERCK CO INC | -54.70 | 26.23 | |
| BRISTOL MYERS S | -39.70 | 17.56 | |
| SCHERING PLOUGH | -58.90 | 13.36 |
